Trials exploring combinations of the MAPK pathway and PI3K/mTOR pathway have proven unsuccessful due to their low efficacy because of low tumour penetrance and high toxicity (Table 4) [77,78,79]. This evidence concerns the gene MTOR and neoplasm.